On Our Own Terms: A Conversation About Medical Aid in Dying, Dignity, and the Choices We're Afraid to Make
On August 5th, 2025, New York State became one of only a handful of states in the country where medical aid in dying is now legal.
For our community — people living with metastatic breast cancer — this is not an abstract policy debate. It's a deeply personal question about how we want to live, and how we want to die.
Developing Story: Triple Negative MBC - Hard Truths, Real Hope with Dr Sarah Premji
Triple negative metastatic breast cancer has long been considered the hardest subtype to treat. That is changing and faster than most patients realize. Dr. Sarah Premji joins Victoria Goldberg to break down two landmark FDA approvals, the science behind antibody-drug conjugates, and what's coming next in the pipeline
Developing Story: Your Cancer's DNA and the Trial Using It to Cure You with Dr. Pedram Razavi
What does it take to cure metastatic breast cancer? According to Dr. Pedram Razavi, it takes a blood test sensitive enough to find one cancer cell in a million, the courage to stop treatment when that signal disappears, and a trial designed to prove the paradigm wrong.
The HERizon-Breast Trial at Memorial Sloan Kettering is doing exactly that — and it's enrolling now.
This is one of the most science-rich episodes of Live from Stage 4 to date. We break down every term, every concept, and every implication in plain language so you don't need a medical degree to understand why this matters.
Developing Story: The Trial That Dares to Say Cure with Dr. Lior Braunstein
Dr. Lior Braunstein, radiation oncologist at Memorial Sloan Kettering, joins Victoria Goldberg and Ellen Landsberger to discuss the ARCHER trial — a groundbreaking study combining surgery and ablative radiation with standard HER2-targeted therapy in patients with oligometastatic HER2-positive breast cancer. The goal: eradicate every last cancer cell before resistance can emerge.
Developing Story: Beyond Camizestrant — The Evolving Landscape of ER+/HER2- MBC with Dr. Sarah Premji
The oral SERD era has arrived, and the treatment landscape for HR+/HER2- metastatic breast cancer is changing fast. Hosts Victoria Goldberg and Abigail Johnston sit down with Dr. Sarah Premji of Sarah Cannon to map out what has shifted beyond SERENA-6, from new FDA approvals and emerging mechanisms to real-world sequencing decisions and the latest trial data. If you are trying to make sense of a rapidly evolving algorithm, this episode is for you.
Developing Story: The Camizestrant Vote, Doctors Weigh In with Dr. Sarah Sammons & Dr. Neil Vasan
When the ODAC voted 6–3 against the camizestrant strategy, the headlines told you what happened — this episode tells you why. We're back for round two with Dr. Sarah Sammons, newly appointed Co-Leader of Breast Oncology at the University of Maryland Greenebaum Comprehensive Cancer Center, and Dr. Neil Vasan, Acting Chair of the ODAC and Director of Translational Research in Breast Cancer at NYU Langone Health, who sat in that room and cast one of the three yes votes. Alongside patient advocates Janice Cowden and Abigail Johnston, we break down the four FDA critiques that drove the vote, what the quality of life data showed and why regulators couldn't act on it, and what the FDA's new August 14th review deadline means for patients. Plus: why this science isn't going anywhere, and what ctDNA-guided treatment could look like in the very near future.
Developing Story: The Camizestrant Vote — When Your Blood Test Knows Before Your Scan Does
Six MBC patient advocates join host Victoria Goldberg to break down the FDA advisory committee's vote on camizestrant and the SERENA-6 trial. The panel unpacks what the vote really means, whether the science of molecular progression is ready for clinical practice, and why patient advocates need a seat at the table before trials are designed.
Front Row Seat: Dr. Fatima Cardoso on Aiming Higher - Hope and the Road to a Cure
For decades, metastatic breast cancer meant one thing: managing the disease. But a new global report — and a bold new charter — say it's time to aim higher. Host Victoria Goldberg sits down with Dr. Fátima Cardoso of the ABC Global Alliance to examine 10 years of hard-won progress, confront the inequalities that have grown worse, and explore why, for the first time, the word cure is entering the conversation.